Note 9 - Segment Information - Summary of Financial Information (Details) - USD ($) |
12 Months Ended | |
|---|---|---|
Apr. 30, 2026 |
Apr. 30, 2025 |
|
| Gross Margin | $ 2,551 | $ 2,470 |
| Research and development | 2,839,012 | 4,386,105 |
| Operations | 8,415,418 | 8,355,041 |
| Loss from operations | (8,412,867) | (8,352,571) |
| Interest expense | (753,041) | (500,453) |
| Other income | 24,033 | 87,795 |
| Total other expense | (729,008) | (412,658) |
| Net loss | (9,141,875) | (8,765,229) |
| Operating Segments [Member] | Single Reportable Segment [Member] | ||
| Gross Margin | 2,551 | 2,470 |
| Clinical and regulatory | 644,157 | 756,189 |
| Research and development | 2,025,445 | 3,456,312 |
| Sales and marketing | 616,323 | 350,167 |
| Operations | 169,410 | 173,604 |
| General and administrative | 4,960,083 | 3,618,769 |
| Loss from operations | (8,412,867) | (8,352,571) |
| Interest expense | 753,041 | 500,453 |
| Other income | (24,033) | (87,795) |
| Total other expense | 729,008 | 412,658 |
| Net loss | $ (9,141,875) | $ (8,765,229) |
| X | ||||||||||
- Definition Amount of expense for clinical and regulatory operations. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|